These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 22920632

  • 1. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 2. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA, Puccio LM, Brydon EW.
    J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
    [Abstract] [Full Text] [Related]

  • 3. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 6. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug 17; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 7. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho Mde J, Comini-Frota ER, Domingues RB, Ferreira ML, Finkelsztejn A, Gama PD, Gomes S, Gonçalves MV, Kaimen-Maciel DR, Morales Rde R, Muniz A, Ruocco HH, Salgado PR, Albuquerque LB, Gama RA, Georgeto S, Lopes J, Oliveira CL, Oliveira FT, Safanelli J, Saldanha PC, Satomi M.
    Arq Neuropsiquiatr; 2013 Oct 17; 71(10):780-2. PubMed ID: 24212514
    [Abstract] [Full Text] [Related]

  • 8. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.
    J Neurol Neurosurg Psychiatry; 2014 Oct 17; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract] [Full Text] [Related]

  • 9. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 17; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 10. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov 17; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 11. Polyoma nephropathy and progressive multifocal leukoencephalopathy in a renal transplant recipient.
    Phillips T, Jacobs R, Ellis EN.
    J Child Neurol; 2004 Apr 17; 19(4):301-4. PubMed ID: 15163098
    [Abstract] [Full Text] [Related]

  • 12. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 17; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 13. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 14. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 15. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
    Mazda ME, Brosch JR, Wiens AL, Bonnin JM, Kamer AP, Mattson DH, Snook RJ.
    Int J Neurosci; 2013 May 17; 123(5):353-7. PubMed ID: 23252596
    [Abstract] [Full Text] [Related]

  • 16. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP, Verhoeff L, Zentjens W, Killestein J, van Munster ET, Barkhof F, van Eijk JJ.
    J Neurol Neurosurg Psychiatry; 2013 Oct 17; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Autopsy diagnosis of progressive multifocal leukoencephalopathy with JC virus-negative CSF after cord blood stem-cell transplantation.
    Sheikh SI, Stemmer-Rachamimov A, Attar EC.
    J Clin Oncol; 2009 Aug 10; 27(23):e46-7. PubMed ID: 19451419
    [No Abstract] [Full Text] [Related]

  • 19. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
    Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC.
    Nervenarzt; 2011 Oct 10; 82(10):1314-9. PubMed ID: 21656322
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.